Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XOF
|
|||
| Former ID |
DIB001002
|
|||
| Drug Name |
NY-ESO-1 vaccine
|
|||
| Synonyms |
Cancer vaccine (peptides), Ludwig Institute; NY-ESO-1b; NY-ESO-1 OLP-4; NY-ESO-1 peptide immunotherapy, Ludwig Institute; NY-ESO-1 vaccine (peptides); NY-ESO-1 DP4 peptide (157-170); NY-ESO-1 vaccine (peptides), Ludwig Institute
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Ludwig Institute for Cancer Research
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cancer/testis antigen 1 (NY-ESO-1) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00199836) A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.. U.S. National Institutes of Health. | |||
| REF 2 | Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.